|
Gene: STOX1 |
Gene summary for STOX1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | STOX1 | Gene ID | 219736 |
Gene name | storkhead box 1 | |
Gene Alias | C10orf24 | |
Cytomap | 10q22.1 | |
Gene Type | protein-coding | GO ID | GO:0000002 | UniProtAcc | Q6ZVD7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
219736 | STOX1 | LZE24T | Human | Esophagus | ESCC | 1.80e-03 | 1.72e-01 | 0.0596 |
219736 | STOX1 | P2T-E | Human | Esophagus | ESCC | 5.53e-63 | 1.20e+00 | 0.1177 |
219736 | STOX1 | P4T-E | Human | Esophagus | ESCC | 4.27e-09 | 2.36e-01 | 0.1323 |
219736 | STOX1 | P8T-E | Human | Esophagus | ESCC | 2.05e-07 | 1.69e-01 | 0.0889 |
219736 | STOX1 | P9T-E | Human | Esophagus | ESCC | 1.88e-05 | 1.63e-01 | 0.1131 |
219736 | STOX1 | P10T-E | Human | Esophagus | ESCC | 3.50e-02 | 6.19e-02 | 0.116 |
219736 | STOX1 | P12T-E | Human | Esophagus | ESCC | 9.44e-07 | 1.97e-01 | 0.1122 |
219736 | STOX1 | P20T-E | Human | Esophagus | ESCC | 8.24e-04 | 1.41e-01 | 0.1124 |
219736 | STOX1 | P26T-E | Human | Esophagus | ESCC | 7.90e-03 | 1.06e-01 | 0.1276 |
219736 | STOX1 | P27T-E | Human | Esophagus | ESCC | 6.31e-57 | 1.13e+00 | 0.1055 |
219736 | STOX1 | P28T-E | Human | Esophagus | ESCC | 2.02e-06 | 1.61e-01 | 0.1149 |
219736 | STOX1 | P30T-E | Human | Esophagus | ESCC | 2.13e-03 | 1.56e-01 | 0.137 |
219736 | STOX1 | P39T-E | Human | Esophagus | ESCC | 3.75e-03 | 1.70e-01 | 0.0894 |
219736 | STOX1 | P42T-E | Human | Esophagus | ESCC | 8.55e-05 | 2.21e-01 | 0.1175 |
219736 | STOX1 | P48T-E | Human | Esophagus | ESCC | 8.56e-12 | 2.38e-01 | 0.0959 |
219736 | STOX1 | P52T-E | Human | Esophagus | ESCC | 1.88e-04 | 1.04e-01 | 0.1555 |
219736 | STOX1 | P57T-E | Human | Esophagus | ESCC | 9.35e-10 | 2.99e-01 | 0.0926 |
219736 | STOX1 | P62T-E | Human | Esophagus | ESCC | 2.57e-02 | 9.51e-02 | 0.1302 |
219736 | STOX1 | P128T-E | Human | Esophagus | ESCC | 1.37e-04 | 1.76e-01 | 0.1241 |
219736 | STOX1 | P130T-E | Human | Esophagus | ESCC | 7.52e-23 | 5.53e-01 | 0.1676 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ESCC: Esophageal squamous cell carcinoma | |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006979111 | Esophagus | ESCC | response to oxidative stress | 303/8552 | 446/18723 | 7.15e-22 | 1.30e-19 | 303 |
GO:0062197111 | Esophagus | ESCC | cellular response to chemical stress | 234/8552 | 337/18723 | 5.37e-19 | 5.97e-17 | 234 |
GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
GO:005105215 | Esophagus | ESCC | regulation of DNA metabolic process | 232/8552 | 359/18723 | 2.40e-13 | 1.13e-11 | 232 |
GO:0010821110 | Esophagus | ESCC | regulation of mitochondrion organization | 107/8552 | 144/18723 | 2.31e-12 | 9.41e-11 | 107 |
GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
GO:0070482111 | Esophagus | ESCC | response to oxygen levels | 218/8552 | 347/18723 | 6.91e-11 | 2.17e-09 | 218 |
GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
GO:0043618111 | Esophagus | ESCC | regulation of transcription from RNA polymerase II promoter in response to stress | 42/8552 | 47/18723 | 3.91e-10 | 1.05e-08 | 42 |
GO:0043620111 | Esophagus | ESCC | regulation of DNA-templated transcription in response to stress | 46/8552 | 53/18723 | 5.17e-10 | 1.33e-08 | 46 |
GO:0036293111 | Esophagus | ESCC | response to decreased oxygen levels | 201/8552 | 322/18723 | 8.37e-10 | 2.04e-08 | 201 |
GO:004578710 | Esophagus | ESCC | positive regulation of cell cycle | 196/8552 | 313/18723 | 9.27e-10 | 2.24e-08 | 196 |
GO:0001666111 | Esophagus | ESCC | response to hypoxia | 192/8552 | 307/18723 | 1.59e-09 | 3.69e-08 | 192 |
GO:00448394 | Esophagus | ESCC | cell cycle G2/M phase transition | 103/8552 | 148/18723 | 3.09e-09 | 6.67e-08 | 103 |
GO:00000864 | Esophagus | ESCC | G2/M transition of mitotic cell cycle | 96/8552 | 137/18723 | 6.00e-09 | 1.23e-07 | 96 |
GO:004593116 | Esophagus | ESCC | positive regulation of mitotic cell cycle | 83/8552 | 121/18723 | 2.78e-07 | 4.08e-06 | 83 |
GO:0071453110 | Esophagus | ESCC | cellular response to oxygen levels | 114/8552 | 177/18723 | 3.63e-07 | 5.06e-06 | 114 |
GO:0036294110 | Esophagus | ESCC | cellular response to decreased oxygen levels | 105/8552 | 161/18723 | 4.20e-07 | 5.73e-06 | 105 |
GO:19040294 | Esophagus | ESCC | regulation of cyclin-dependent protein kinase activity | 69/8552 | 98/18723 | 6.04e-07 | 7.91e-06 | 69 |
Page: 1 2 3 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STOX1 | SNV | Missense_Mutation | novel | c.1622N>T | p.Arg541Ile | p.R541I | Q6ZVD7 | protein_coding | deleterious(0.01) | benign(0.325) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
STOX1 | SNV | Missense_Mutation | c.406N>A | p.Ala136Thr | p.A136T | Q6ZVD7 | protein_coding | tolerated(0.08) | benign(0.357) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
STOX1 | SNV | Missense_Mutation | novel | c.910G>T | p.Asp304Tyr | p.D304Y | Q6ZVD7 | protein_coding | deleterious(0) | possibly_damaging(0.87) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STOX1 | SNV | Missense_Mutation | c.1487N>A | p.Pro496His | p.P496H | Q6ZVD7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
STOX1 | SNV | Missense_Mutation | c.2387G>T | p.Arg796Ile | p.R796I | Q6ZVD7 | protein_coding | tolerated(0.19) | benign(0.007) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
STOX1 | SNV | Missense_Mutation | c.2246N>A | p.Arg749His | p.R749H | Q6ZVD7 | protein_coding | tolerated(0.49) | benign(0) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
STOX1 | SNV | Missense_Mutation | c.2697N>C | p.Gln899His | p.Q899H | Q6ZVD7 | protein_coding | tolerated(0.16) | benign(0.007) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
STOX1 | SNV | Missense_Mutation | rs200722232 | c.442N>T | p.Arg148Cys | p.R148C | Q6ZVD7 | protein_coding | deleterious(0) | possibly_damaging(0.471) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
STOX1 | SNV | Missense_Mutation | novel | c.2166G>T | p.Gln722His | p.Q722H | Q6ZVD7 | protein_coding | deleterious(0) | benign(0.043) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STOX1 | SNV | Missense_Mutation | c.2387N>T | p.Arg796Ile | p.R796I | Q6ZVD7 | protein_coding | tolerated(0.19) | benign(0.007) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |